Janssen Says Investigational Treatment for Myeloma Gets FDA Breakthrough Designation
December 06 2019 - 5:03PM
Dow Jones News
By Stephen Nakrosis
The Janssen Pharmaceutical Cos. of Johnson & Johnson said
Friday the U.S. Food and Drug Administration granted Breakthrough
Therapy Designation for JNJ-68284528, an investigational therapy to
treat certain myeloma patients.
Janssen said the designation was supported by results from its
Phase 1b/2 CARTITUDE-1 study, a multicenter clinical trial
evaluating the safety and efficacy of JNJ-4528 currently active in
the U.S.
"The primary objective of the Phase 1b portion of the study is
to characterize the safety of JNJ-4528 and confirm the dose for
future clinical trials," the company said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 06, 2019 16:48 ET (21:48 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
